Valeria Fiore

The consultation on the concept paper on human #phage therapies will be open until 31 March. Have your say in the first EMA guideline on these medicines, that could help us fight #antibioticresistance and open up new routes to treating infections. 👇 #ema-inpage-item-64733" target="_blank" rel="nofollow noopener">ema.europa.eu/en/development…

Today we have published our report on the antimicrobial potential of bacteriophages. It calls for steps to develop their potential as an alternative to antibiotics that are attracting growing resistance: committees.parliament.uk/publications/4…

📣CALLING ALL UK RESEARCHERS & SCIENTISTS! I will be answering all your questions about the UK’s deal with Horizon Europe this afternoon on LinkedIn, so click the link below to leave your comments & I will strive to respond to as many as I can 👇 linkedin.com/posts/george-f…

An important read in the @FT with BGMA CEO @MarkSamuelsUK: With 85 biologics set to lose patent exclusivity in the next 5 years, the Govt must address its #VPAS Scheme - or risk missing out on £1bn in NHS savings & UK leadership in #biosimilars: ft.com/content/a09cb0…

“It’s just around the next corner”, Stella assures MEPs - after three postponements

At #DIAEurope2023. Very interesting discussions so far, and these are the hopes for innovation in Europe that attendees shared this morning... 😊 #WomenInScience #WomenInSTEM

HM Treasury announced today that we'll receive £10m to help bring innovative new #medicines and #medical technologies to UK patients more quickly. This will accelerate routes for bringing cutting-edge medical products onto the market: gov.uk/government/new…

Looking forward to covering my first in-person conference for @apmhealtheurope tomorrow and on Wednesday! #AdTherapies23 will take place at the ExCeL centre in London. Come say hello if you see me 👀 #london #conference #celltherapy #genetherapy

The high rebate rates companies have to pay back to Government for medicine sales are a false economy, says @WPI_Strategy. Read more abpi.org.uk/publications/f…

Over the past few months there’s been lots of attention on how competitive the UK is for #LifeSciences. The boss was on @BBCr4today setting this out. We need the sector to drive health & growth. Check out @ABPI_UK thread below for where we are & how we maximise the opportunities.

@ChemistDruggist Happy to have contributed to the 2022 C+D team's success with my work on the temporary pharmacy closures 🙂

C+D scoops up two gongs for GPhC exam coverage and temporary closure exposé bit.ly/3WQS7xj

Today we have called for a full stop to further rises to the already record revenue clawbacks in the UK. Doing so is a fundamental first step to reassuring investors about the UK’s ambition to halt the contraction of UK life sciences. abpi.org.uk/media/news/202…

📢@MHRAgovuk listened to our concerns and will not introduce new fees for the Innovative Licensing and Access Pathway (ILAP) and Clinical Trials – Complex Amendments.

📢 From today, all initial clinical trial applications in the EU 🇪🇺 must be submitted via #CTIS! All clinical trial sponsors will now use the same system and follow the same procedures to apply for the authorisation of a #clinicaltrial. ➡️ ema.europa.eu/en/news/use-cl…

Interesting development. Thoughts? #ATMPs #CGT #medicines

Looking forward to interviewing key experts from @Phacilitate’s #AdvancedTherapiesWeek to learn all about the latest developments in the space. I have a few more slots available so please don’t hesitate to reach out. It would be great to connect with some old and new faces #ATW23

Writing a story on #endometriosis and #pain management for my journalism coursework. I would love to hear about your #experience. DMs open. #journorequest #Medical #stigma

Are you aware of other companies that are asking the DHSC to leave the #VPAS by end of year, especially in light of the new repayment rate? DMs are open, or you can reach me at valeria.fiore@apmnews.com Thanks!

Revealed: The @DHSCgovuk told @apmhealtheurope which five companies are planning to leave the UK's voluntary scheme for branded #medicines pricing and access (#VPAS). It comes as it announced the #repayment rate for the scheme is to soar to 26.5% next year.